Evidence map›Paper›PMID 33686556›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2021

Characterization of an osteomyelitis case caused by dalbavancin, ceftaroline, and vancomycin non-susceptible methicillin-resistant Staphylococcus aureus.

Elias Dahdouh, Beatriz Díaz-Pollán, Iker Falces-Romero, Jesús Mingorance, Rosa Gómez-Gil

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elias DahdouhClinical Microbiology and Parasitology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain. elie.dahdouh@idipaz.es.ORCID http://orcid.org/0000-0003-2309-4129
Beatriz Díaz-PollánClinical Microbiology and Infectious Diseases Unit, Hospital Universitario La Paz, Madrid, Spain.
Iker Falces-RomeroClinical Microbiology and Parasitology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain.
Jesús MingoranceClinical Microbiology and Parasitology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain.
Rosa Gómez-GilClinical Microbiology and Parasitology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case of osteomyelitis due to methicillin-resistant Staphylococcus aureus (MRSA) that is also non-susceptible to vancomycin, dalbavancin, ceftaroline, and ceftobiprole, in the absence of exposure to the latter three antibiotics. It was isolated from a patient with a 26-year history of cranial surgeries and episodes of osteomyelitis. Whole-genome sequencing was performed. It was found to belong to ST247 and the mecA gene was detected within the SSCmec type I (1B) gene cassette that lacked the E447K mutation known to produce resistance to ceftobiprole and ceftaroline. However, mutations in other genes related to resistance to these antibiotics were found.

Indexed as

AdultAnti-Bacterial AgentsCeftarolineCephalosporinsDrug Resistance, Multiple, BacterialHumansMaleMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsOsteomyelitisTeicoplaninVancomycinWhole Genome SequencingAnti-Bacterial AgentsCeftarolineCephalosporinsdalbavancinTeicoplaninVancomycinCeftarolineCeftobiproleDalbavancinMRSAOsteomyelitisStaphylococcus aureus

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.